# OnCo record paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017" ;
  schema:name "HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma"@en ;
  schema:description "Busulfan and melphalan as the high-dose conditioning before stem cell rescue gave better event-free survival and less severe toxicity than the carboplatin-etoposide-melphalan regimen in high-risk neuroblastoma, becoming Europe's standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(17)30070-0>, <https://pubmed.ncbi.nlm.nih.gov/28259608/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(17)30070-0> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Ladenstein R, Pötschger U, Pearson ADJ, et al." ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:drugs <https://onco.cc/drugs/busulfan/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/> ;
  onco:trials <https://onco.cc/trials/hr-nbl1/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .